Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.7147
+0.0147 (2.10%)
At close: Aug 13, 2025, 4:00 PM
0.7151
+0.0004 (0.06%)
Pre-market: Aug 14, 2025, 8:41 AM EDT
Xilio Therapeutics Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Xilio Therapeutics stock ranges from a low of $2.00 to a high of $4.00. The average analyst price target of $3.00 forecasts a 319.76% increase in the stock price over the next year.
Price Target: $3.00 (+319.76%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Xilio Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $2 | Buy | Initiates | $2 | +179.84% | Aug 6, 2025 |
| Raymond James | Raymond James | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +459.68% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +879.43% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +879.43% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +1,299.19% | Jan 27, 2023 |
Financial Forecast
Revenue This Year
25.38M
from 6.34M
Increased by 300.08%
Revenue Next Year
25.86M
from 25.38M
Increased by 1.87%
EPS This Year
-0.62
from -1.09
EPS Next Year
-0.81
from -0.62
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.4M | 26.9M | 26.9M | ||
| Avg | 25.4M | 25.9M | 25.9M | ||
| Low | 24.6M | 25.1M | 25.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 315.9% | 5.9% | 4.0% | ||
| Avg | 300.1% | 1.9% | - | ||
| Low | 288.2% | -1.2% | -3.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.64 | -0.84 | -1.31 |
| Avg | -0.62 | -0.81 | -1.26 |
| Low | -0.60 | -0.78 | -1.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.